

Aug. 13, 2021

The Honorable Mark Warner
703 Hart Senate Office Building
Washington, DC 20510

The Honorable Tim Scott
104 Hart Senate Office Building
Washington, DC 20510

Dear Senators Warner and Scott:

I am writing today to offer [Vizient's](#) support for S. 2652, the Preserving Patient Access to Home Infusion Act. Your bipartisan legislation would offer important clarifications to the law that established the Medicare home infusion benefit and provide for greater patient access to infusion therapies in their own homes.

Vizient, Inc. is the nation's largest health care performance improvement company. Vizient provides solutions and services that improve the delivery of high-value care by aligning cost, quality and market performance for more than 50% of the nation's acute care providers, which includes 95% of the nation's academic medical centers, and more than 20% of ambulatory providers. Vizient provides expertise, analytics, and advisory services, as well as a contract portfolio that represents more than \$100 billion in annual purchasing volume, to improve patient outcomes and lower costs. Headquartered in Irving, Texas, Vizient has offices throughout the United States.

As the Centers for Medicare and Medicaid Services (CMS) has implemented the new Medicare home infusion benefit approved as part of the 21st Century Cures Act, the agency narrowly interpreted the law. Specifically, CMS will only reimburse a home infusion supplier for services if a health care provider (e.g., nurse) is physically present in the patient's home and an infusion drug is administered on the same day. This is impractical for both providers and patients. Your bill would clarify the definition of "Infusion drug administration calendar day" so that a nurse (or other provider) would not be required to be physically present in the home to qualify for Medicare reimbursement. The bill would also provide more flexibility by allowing Physician Assistants and Nurse Practitioners to establish and review home infusion plans of care.

We believe your legislation helps support more widespread adoption of this treatment option for patients. We are pleased to offer our endorsement for your legislation and urge its passage.

Thank you for your ongoing leadership on this issue. Please do not hesitate to contact me at shoshana.krilow@vizientinc.com or 202-354-2607 if you have any questions about Vizient or if there is any way we can be of assistance in advancing your important legislation.

Sincerely,



Shoshana Krilow
Senior Vice President, Public Policy & Government Relations